ADC Therapeutics SA
-
Ticker
ADCT
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in Lausanne, Switzerland
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of those affected by cancer with their next-generation, targeted antibody drug conjugates (ADCs). With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, they are working to address significant unmet medical needs and improve outcomes for
…More those with difficult-to-treat hematological cancers and solid tumors. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC). Their highly skilled global team is committed to confronting cancer with the full potential of their science, bringing unique, targeted therapies and hope to patients and their families.
ADC Therapeutics SA
Most Recent Responsibility Report
MOST RECENT
2021 Environmental, Social & Governance Report
Our service enables potential investors to review the most recent and archived ADC Therapeutics SA Sustainability Report, ADC Therapeutics SA Corporate Social Responsibility Report, ADC Therapeutics SA CSR Report, ADC Therapeutics SA Corporate Responsibility, ADC Therapeutics SA CR Report, ADC Therapeutics SA Citizenship Report, ADC Therapeutics SA ESG Report, and ADC Therapeutics SA Environmental Report online.